Skip to content

Intellia Therapeutics

US · NTLA #2899 by market cap Listed 2016
10.00 +0.48 +5.04%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:01

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions decreased by 10 in the most recent period (2026/Q3).
  • Total institutional ownership fell 0.9 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
103.74% -0.91pp
Institutions
382 -10
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund72.29%
Hedge Fund16.46%
Public Company7.92%
VC/PE Fund3.48%
Private Company2.73%
Individual/Insider1.57%
Government Pension Fund0.45%
Insurance Company0.26%
Family Office/Trust0.14%

Top holders as of 2026-09-30

BlackRock 11.42% · 16.04M sh
ARK Investment Management LLC 11.35% · 15.93M sh
State Street Global Advisors 5.56% · 7.81M sh
Vanguard Portfolio Management, LLC 5.26% · 7.39M sh
D. E. Shaw & Co., L.P. 4.59% · 6.44M sh
Vanguard Capital Management, LLC 4.30% · 6.04M sh
Two Sigma Investments, LP 3.73% · 5.24M sh
FMR 3.34% · 4.68M sh
RA Capital Management, L.P. 3.23% · 4.53M sh
Regeneron Pharmaceuticals, Inc. 2.64% · 3.70M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 31 buys · 19 sells

NameRoleStake
John Leonard Chief Executive Officer 0.85%
Fred Cohen Independent Director 0.14%
Edward Dulac Chief Financial Officer 0.11%
William Chase Independent Director 0.10%
Eliana Clark Former Executive VP & Chief Technical Officer 0.07%
David Lebwohl Former Chief Medical Officer 0.06%
James Basta General Counsel 0.05%
Birgit Schultes Chief Scientific Officer 0.05%
Michael Dube Vice President 0.05%
Derek Hicks Executive VP & Chief Business Officer 0.04%
Laura Sepp-Lorenzino Former Advisor 0.03%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-01 John Leonard Chief Executive Officer Automatic Disposition -9,000 $11.99
2026-10-25 Jing Marantz EVP & Chief Medical Officer Other Acquisition +199,822 --
2026-10-25 Jing Marantz EVP & Chief Medical Officer Other Derivative Acquisition +275,061 $11.26
2026-10-01 Michael Dube Vice President Open Market Disposition -1,864 $12.43
2026-08-20 John Leonard Chief Executive Officer Automatic Disposition -22,675 $12.60–13.00
2026-08-19 John Leonard Chief Executive Officer Intent to Sell (Form 144) -22,675 $12.95
2026-07-21 Edward Dulac Chief Financial Officer Open Market Disposition -8,111 $11.25
2026-07-01 Edward Dulac Chief Financial Officer Automatic Disposition -4,677 $18.00
2026-06-30 Michael Dube Vice President Open Market Disposition -2,641 $16.78
2026-06-08 Fred Cohen Independent Director Other Acquisition +9,200 --
2026-06-08 Fred Cohen Independent Director Other Derivative Acquisition +13,300 $12.89
2026-06-08 Franciscus A. G. Verwiel Independent Chairperson Other Acquisition +9,200 --
2026-06-08 Franciscus A. G. Verwiel Independent Chairperson Other Derivative Acquisition +13,300 $12.89
2026-06-08 William Chase Independent Director Other Acquisition +9,200 --
2026-06-08 William Chase Independent Director Other Derivative Acquisition +13,300 $12.89
2026-06-08 Brian Goff Independent Director Other Acquisition +9,200 --
2026-06-08 Brian Goff Independent Director Other Derivative Acquisition +13,300 $12.89
2026-06-08 Jesse Goodman Independent Director Other Acquisition +9,200 --
2026-06-08 Jesse Goodman Independent Director Other Derivative Acquisition +13,300 $12.89
2026-06-08 Georgia Keresty Independent Director Other Acquisition +9,200 --

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:01:29 · For reference only, not investment advice and not tailored to your situation.

Intellia Therapeutics discussion 0 comments

Add a comment